State Street SPDR S&P Biotech ETF
$146.80−4.60 (−3.04%)
- 0.35%
- $10.3B
- +44.8%
- 0.36%
- 9.1M sh
- $153.72
- low $103.43high $169.89
The ETF.net XBI Grade
A
Score 81 out of 100
- 1 of 17
Score 81 of 100 falls in the A band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.A81 out of 100Rank 3 of 17Mission
Whether the fund did what it promised, tested against its stated mandate.A85 out of 100Rank 3 of 9Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.C47 out of 100Rank 10 of 17Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.A100 out of 100Rank 1 of 17Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A88 out of 100Rank 2 of 17Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.A89 out of 100Rank 1 of 17
Our read on XBI
ABiotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.
The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.
Why people hold it
- Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
- 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
- Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
- A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.
Worth knowing
- Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comindexes.nasdaqomx.com
- Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
- One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com
XBI Holdings
- Stocks
- 165
- 17%
- MRNA
Sectors
- Health Care99.3%
- Financials0.7%
Geography
- United States95.43%
- Switzerland1.45%
- Ireland1.40%
- United Kingdom1.25%
- Netherlands0.46%
XBI Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
XBI$14,481
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | XBI |
|---|---|
| Year to date | +24.3% |
| 1 month | −3.1% |
| 3 months | −4.8% |
| 1 year | +44.8% |
| 3 years | +30.4% |
| 5 years | +4.1% |
| 10 years | +9.6% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | XBI |
|---|---|---|
| 2026 YTD | +24.3% | |
| 2025 | +35.9% | |
| 2024 | +1.0% | |
| 2023 | +7.6% | |
| 2022 | −25.9% | |
| 2021 | −20.5% | |
| 2020 | +48.3% |
XBI in the news
XBI Dividends
- 0.36%
- $0.54
- $0.14 per share
- Twice a year
Distribution history
XBI Risk
- 25.6%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.97
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −53.2%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 1.10
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
XBI Cost
0.35%
XBI0.35%
- The middle half of Biotech & Genomics funds
- Median 0.47%
2 of the 17 Biotech & Genomics funds charge less.
Other funds in Biotech & Genomics
- AIBBQInvesco Nasdaq Biotechnology ETFExpense ratio 0.19%1 year return +37.5%
- ABBPVirtus Biotech ETFExpense ratio 0.34%1 year return +47.9%
- AIBBiShares Biotechnology ETFExpense ratio 0.44%1 year return +36.5%
- BBBHVanEck Biotech ETFExpense ratio 0.35%1 year return +39.7%
- BFBTFirst Trust NYSE Arca Biotechnology Index FundExpense ratio 0.55%1 year return +44.7%